Balloon Valvuloplasty Devices Market To Reach $3.02 Billion By 2030

Balloon Valvuloplasty Devices Market Growth & Trends

The global balloon valvuloplasty devices market size is expected to reach USD 3.02 billion by 2030, registering a CAGR of 4.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cardiovascular diseases, including valvular heart diseases, new product launches, regulatory approvals, and advanced healthcare infrastructure, drives the demand for balloon valvuloplasty devices in North America. Rheumatic heart disease (RHD) is a serious cardiovascular condition that arises from damage to the heart valves due to rheumatic fever.

According to a report published by the American Heart Association in April 2024, valvular heart disease (VHD) is among the most prevalent health conditions in the U.S., affecting about 2.5% of the adult population. Aortic and mitral valve diseases are the most diagnosed types of VHD, further emphasizing the critical need for effective treatment options like balloon valvuloplasty devices to address this growing health concern.

Increasing awareness and screening programs fuel the market's growth. For instance, in September 2024, the Global Heart Hub initiated campaigns highlighting the rising prevalence of heart valve disease, which is expected to double by 2040 and triple by 2060. These efforts stress the critical role of early detection through regular medical check-ups. The organization aims to inform the public about the symptoms and available treatments, such as balloon valvuloplasty.

 Request a free sample copy or view report summary: Balloon Valvuloplasty Devices Market Report

Balloon Valvuloplasty Devices Market Report Highlights

• Based on application, the aortic valve stenosis segment held the largest share, over 64%, in 2023. The global rise in the incidence of valvular heart diseases and technological advancements drive the segment's growth

• Based on end use, the hospital segment held the largest revenue share at 57.4% in 2023. The rising incidence of valvular heart diseases globally necessitates advanced solutions within hospitals to manage patient care effectively

• North America dominated the market with a share of 41.4% in 2023, owing to the rising cases of cardiovascular diseases, including valvular heart diseases. Product launches, regulatory approvals, and advanced healthcare infrastructure drive the demand for balloon valvuloplasty devices

• Market players operating in the balloon valvuloplasty devices market include B. Braun Interventional Systems, Inc., BD Interventional, Edwards Lifesciences, Boston Scientific Corporation, Getinge, Toray International America, Inc., Stryker, BrosMed Medical, Medtronic, Terumo Corporation, Philips

Balloon Valvuloplasty Devices Market Segmentation

Grand View Research has segmented the balloon valvuloplasty devices market based on application, end-use, and region:

Balloon Valvuloplasty Devices Application Category Outlook (Revenue, USD Million, 2018 - 2030)

• Aortic Valve Stenosis

• Pulmonary Valve Stenosis

Balloon Valvuloplasty Devices End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Ambulatory Surgical Centers (ASCs)

• Cardiac Catheterization Labs

Balloon Valvuloplasty Devices Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Balloon Valvuloplasty Devices Market

• B. Braun Interventional Systems, Inc.

• BD Interventional

• Edwards Lifesciences

• Boston Scientific Corporation

• Getinge

• Toray International America, Inc.

• Stryker

• BrosMed Medical

• Medtronic

• Terumo Corporation

• Philips